CYP2D6 and tamoxifen: Awaiting the denouement

Journal of Clinical Oncology

Volumn 29, Issue 34, 2011, Pages 4589-4590

  Brauch, Hiltrud B ^a,b   Schroth, Werner ^a,b   Ingle, James N ^c   Goetz, Matthew P ^c  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BIOLOGICAL MARKER; CYTOCHROME P450 2D6; ENDOXIFEN; TAMOXIFEN;

CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER THERAPY; CLINICAL STUDY; DRUG METABOLISM; DRUG PROTEIN BINDING; FOLLOW UP; GENOTYPE; HOMOZYGOSITY; LETTER; MONOTHERAPY; PEER REVIEW; PHARMACOGENETICS; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; FEMALE; HUMANS; TAMOXIFEN;

EID: 83355169746     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.8611     Document Type: Letter

References (10)

1. Irvin WJ Jr, Walko CM, Weck KE, et al: Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: A multicenter study. J Clin Oncol 29:3232-3239, 2011
2. Rae JM: Personalized tamoxifen: What is the best way forward? J Clin Oncol 29:3206-3208, 2011
3. Rae JM, Drury S, Hayes DF, et al: Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. Cancer Res 70, 2010 (suppl; abstr S1-7)
4. Leyland-Jones B, Regan MM, Bouzyk M, et al: Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. Cancer Res 70, 2010 (suppl; abstr S1-8)
5. Goetz MP, Rae JM, Suman VJ, et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318, 2005
6. Schroth W, Goetz MP, Hamann U, et al: Association between CYP2D6 polymorphisms and outcomes among women with early breast cancer treated with tamoxifen. JAMA 302:1429-1436, 2009
7. Mürdter TE, Schroth W, Bacchus-Gerybadze L, et al: Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708-717, 2011
8. Madlensky L, Natarajan L, Tchu S, et al: Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89:718-725, 2011
9. Dowsett M, Allred C, Knox J, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059-1065, 2008
10. Goetz MP, Ames MM, Gnant M, et al: Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial. Cancer Res 69, 2008 (suppl; abstr 57)